Once-Weekly intravenous liposomal amphotericin B (AmBisome) for fungal prophylaxis in pediatric high-risk hematologic malignancy: A retrospective evaluation of safety and tolerability

Study ID
STU 022013-003

Cancer Related

Healthy Volunteers

Study Sites

  • Children’s Medical Center (Dallas, Plano, Southlake)

Shahenaaz Sunderji

Principal Investigator
Martha Stegner, M.D.


For this project, we will perform a retrospective review of all patients treated for high-risk hematologic malignancy from 12/5/2011 to 12/5/2012. We will describe patient characteristics, including cancer diagnosis, age at diagnosis, sex, race, weight, chemotherapy protocol, and survival data. For patients who received at least one dose of prophylactic amBisome, we will report number of doses received, toxicities, and incidence of iFi. For those who did not receive weekly amBisome, we will report reasons for exclusion, and incidence of iFi. We will also review patients treated at CMC during the year prior (12/5/2010-12/5/2011) and report patient characteristics, fungal prophylaxis, if any, toxicity, and incidence of iFi.

Participant Eligibility

- Diagnosis of high-risk hematologic malignancy (including high risk B-precursor acute lymphoblastic leukemia/lymphoma, T-cell acute lymphoblastic leukemia/lymphoma, acute myeloid leukemia, relapsed/refractory leukemia).
- Treatment at Children[Single Quote]s Medical Center with intensive chemotherapy and/or hematopoietic stem cell transplant during the four-year period, 12/5/2008-12/5/2012.